The detrimental role of PERK activation in stroke outcomes is often implicated by pharmacologic studies in which protective effects are associated with reduced levels of PERK branch components such as p-eIF2α, ATF4, and CHOP [61,62,63]. This evidence concerns the gene ATF4 and Stroke.